Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session

65P - The role of desmocollin-3 glycoprotein in EMT-driven melanomagenesis: Implications for progression and patient outcome

Date

07 Dec 2024

Session

Poster Display session

Presenters

Saber Imani

Citation

Annals of Oncology (2024) 35 (suppl_4): S1426-S1431. 10.1016/annonc/annonc1686

Authors

M. Maghsoudloo

Author affiliations

  • The Research Center For Preclinical Medicine,, Key Laboratory of Epigenetics and Oncology, The Research Center for Preclinical Medicine, Southwest Medical University, Luzhou, Sichuan, China, 646000 - Luzhou/CN

Resources

This content is available to ESMO members and event participants.

Abstract 65P

Background

Malignant melanoma (MM) poses a significant clinical challenge necessitating improved diagnostic markers and therapeutic targets. Desmocollin-3 (DSC3), part of the desmosomal cadherin family, plays a role in epithelial-mesenchymal transition (EMT)-driven tumorigenesis. This study explores DSC3's functional and clinical significance as a diagnostic marker and therapeutic target in MM.

Methods

In a study 35 participants were divided into control, primary melanoma, and advanced MM groups. Tissue samples were collected for RNA isolation and qRT-PCR to measure DSC3 expression. Immunohistochemistry staining assessed DSC3 levels. Melanoma cell lines were transduced with DSC3-targeting shRNA, validated via qRT-PCR and Western blotting. Invasion, migration, cell cycle, and real-time cell analysis were performed. Protein levels were examined via Western blotting. Whole Genome Sequencing (WGS) identified genomic alterations. In silico mutation analysis evaluated DSC3 mutations.

Results

Our investigation consistently demonstrates the downregulation of DSC3 during melanomagenesis, affecting both melanoma cell lines and an independent tissue cohort. Furthermore, reduced levels of DSC3 are strongly linked with unfavorable clinical outcomes and are significantly correlated with disease severity and key metastatic biomarkers, including BRAF and NRAS mutations. Functional experiments provide compelling evidence that a decrease in DSC3 expression enhances cell scattering, invasion, and migration, thereby facilitating EMT-driven tumor progression and metastasis. Remarkably, whole-exome sequencing uncovers novel somatic loss-of-function mutations in DSC3, offering valuable insights into potential genetic drivers of melanoma pathogenesis.

Conclusions

Our study not only provides crucial insights into the role of DSC3 in melanoma but also underscores its relevance within the context of unraveling the mysteries of glycans in humans and pathogens. This comprehensive understanding sets the stage for the development of targeted therapies with a specific emphasis on glycoproteins and glycosylation, promising improved outcomes for MM patients.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.